As an insulin‐sensitising agent, metformin improves insulin sensitivity and glucose uptake in T2DM [11, 12] while also being recognised as a recommended adjunct therapy in overweight T1DM patients, potentially reducing cardiovascular disease (CVD) risk [13, 14]. This evidence concerns the gene INS and type 2 diabetes mellitus.